Diabetogia: Individuals screened with multiple autoantibodies have a significant lying difference in risk of developing type 1 diabetes

Children with multiple autoantibodies (mab) have a very high risk of developing type 1 diabetesWe assessed whether people with monoclonal antibodies detected through screening were also at high risk, and how the risk varied with age, autoantibody type, and metabolic stateresearchers analyzed the Type 1 type 1 type 1 type 1 type 1 type of type 1 type 1 type 1 type 1 type of disease, using monoto-resistance (nal s 1815; age: 12.35 to 9.39 years old)Depending on age, the type/number of autoantibodies (insulin autoantibodies (IAA), glutamate deprosar autoantibodies (GADA), insulin tumor-related antigen 2 autoantibodies (IA-2A) or zinc transport-protein 8 autoantibodies (ZnT8A)) assessthe risk of type 1 diabetes Index60 (abdominal C peptide, 60-minute glucose and 60-minute C combined peptide measure)Cox regression and cumulative incidence curves were used in this cohort studystudies showed a negative correlation between the age of mAbs and the risk of type 1 diabetes (HR 0.97 (95% CI 0.96, 0.99)In the participants with two autoantibodies, the risk of type 1 diabetes was lower in patients with GADA (HR 0.35 (95% CI 0.22, 0.57)) and those with IA-2A had a higher risk of type 1 diabetes (HR 2.82 (95% CI 1.76, 4.51))People with IAA and GADA had only a 17 percent risk of developing type 1 diabetesThe risk of Index60 1.0 (HR 0.23 (95% CI 0.19, 0.30)) is significantly reduced compared to patients with an Index60 value of 1.0Among those aged 125/15 with 12.0 years of age who were GADA-positive, IA-2A negative, Index60,1.0 and 12.0 years, the risk of type 1 diabetes in five years was 8%in individuals screened for monoclonal antibodies, the risk of type 1 diabetes varies significantly due to age, autoantibody type, and metabolic statusA significant proportion of older children and adults carry monoclonal antibodies and have a lower risk of developing type 1 diabetes after 5 yearsWith this knowledge, clinical trials to prevent type 1 diabetes can better target those who are most likely to progress